Sullivan Mark bought DFTX
June 22, 2026 · Form 4 insider transaction
Sullivan Mark bought 62,500 shares of Definium Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
62,500
Price
$0.00
Total value
N/A
InsiderSullivan Mark
RoleOfficer
SecurityCommon Shares
Transaction codeA: Grant or award
Transaction dateJune 22, 2026
Filing dateJune 22, 2026
Shares owned after333,579
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.